1. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial
   Cunliang Wang et al, 2022, BMC Cancer CrossRef
2. Anaphylaxis caused by pegylated recombinant human granulocyte colony-stimulating factor
   Chen Chen et al, 2023, Journal of Oncology Pharmacy Practice CrossRef
3. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)
   Jun Wang et al, 2021, Precision Radiation Oncology CrossRef
4. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
   Jun Wang et al, 2023, Precision Radiation Oncology CrossRef
5. Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China
   Genzhu Wang et al, 2021, Medicine CrossRef
6. Hematological Side Effects
   Ainaz Sourati et al, 2017, Acute Side Effects of Radiation Therapy CrossRef
7. Avaliação ultraestrutural de agulhas e seu papel no conforto durante a administração subcutânea de medicamentos
   Iuri Bastos Pereira et al, 2018, Revista da Escola de Enfermagem da USP CrossRef
8. A prospective, randomized clinical trial of emergency treatment of chemotherapy‐induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF)
   Xiaofeng Huang et al, 2023, British Journal of Clinical Pharmacology CrossRef